These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38598812)

  • 1. Acoramidis in Transthyretin Amyloid Cardiomyopathy.
    Groothof D; Nienhuis HLA; Bakker SJL
    N Engl J Med; 2024 Apr; 390(14):1346. PubMed ID: 38598812
    [No Abstract]   [Full Text] [Related]  

  • 2. Acoramidis in Transthyretin Amyloid Cardiomyopathy.
    Verbeeck J; De Backer M; Buyse M
    N Engl J Med; 2024 Apr; 390(14):1345-1346. PubMed ID: 38598811
    [No Abstract]   [Full Text] [Related]  

  • 3. Acoramidis in Transthyretin Amyloid Cardiomyopathy. Reply.
    Gillmore JD; Lystig T; Fox JC
    N Engl J Med; 2024 Apr; 390(14):1346-1347. PubMed ID: 38598813
    [No Abstract]   [Full Text] [Related]  

  • 4. Letter by Baldovino et al Regarding Article, "Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy".
    Baldovino S; Costanzo P; Roccatello D
    Circ Heart Fail; 2022 Jul; 15(7):e009617. PubMed ID: 35748294
    [No Abstract]   [Full Text] [Related]  

  • 5. Letter by Rozenbaum et al Regarding Article, "Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy".
    Rozenbaum MH; Kemner J; Parasuraman B
    Circulation; 2020 Oct; 142(15):e210-e211. PubMed ID: 33044864
    [No Abstract]   [Full Text] [Related]  

  • 6. Response by Kazi et al to Letter Regarding Article, "Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy".
    Kazi DS; Bellows BK; Spertus JA; Baron SJ; Shen C; Cohen DJ; Yeh RW; Arnold SV; Sperry BW; Maurer MS; Shah SJ
    Circulation; 2020 Oct; 142(15):e212-e213. PubMed ID: 33044859
    [No Abstract]   [Full Text] [Related]  

  • 7. Tafamidis Treatment Decreases
    Yu AL; Chen YC; Tsai CH; Chao CC; Su MY; Juang JJ; Lee MJ; Hsieh ST; Cheng MF; Lin YH
    JACC Cardiovasc Imaging; 2023 Jun; 16(6):866-867. PubMed ID: 36881423
    [No Abstract]   [Full Text] [Related]  

  • 8. Tafamidis for transthyretin amyloid cardiomyopathy: the solution or just the beginning of the end?
    Falk RH
    Eur Heart J; 2019 Mar; 40(12):1009-1012. PubMed ID: 30668704
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of ATTR cardiomyopathy with a TTR specific antisense oligonucleotide, inotersen.
    Dasgupta NR; Benson MD
    Amyloid; 2019; 26(sup1):20-21. PubMed ID: 31343363
    [No Abstract]   [Full Text] [Related]  

  • 10. Oral Therapy for the Treatment of Transthyretin-Related Amyloid Cardiomyopathy.
    Nuvolone M; Girelli M; Merlini G
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of doxycycline and ursodeoxycholic acid on transthyretin amyloidosis.
    Wixner J; Pilebro B; Lundgren HE; Olsson M; Anan I
    Amyloid; 2017 Mar; 24(sup1):78-79. PubMed ID: 28042702
    [No Abstract]   [Full Text] [Related]  

  • 12. Blinded potency comparison of transthyretin kinetic stabilisers by subunit exchange in human plasma.
    Nelson LT; Paxman RJ; Xu J; Webb B; Powers ET; Kelly JW
    Amyloid; 2021 Mar; 28(1):24-29. PubMed ID: 32811187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Racial and Genetic Differences in Presentation of Transthyretin Amyloid Cardiomyopathy With Impaired Left Ventricular Function.
    Martyn T; Saef J; Dey AR; Khedraki R; Jain V; Collier P; Jaber WA; Estep JD; Hanna M; Tang WHW
    JACC Heart Fail; 2022 Sep; 10(9):689-691. PubMed ID: 36049818
    [No Abstract]   [Full Text] [Related]  

  • 14. Hereditary transthyretin amyloidosis associated with a transthyretin variant Thr59Arg.
    Watanabe T; Obayashi K; Misumi Y; Tasaki M; Shinriki S; Ando T; Akagami T; Ueda M; Yamashita T; Hirotani S; Ando Y
    Amyloid; 2017 Mar; 24(sup1):119. PubMed ID: 28434332
    [No Abstract]   [Full Text] [Related]  

  • 15. Redefining Prognosis of Transthyretin Cardiomyopathy in the Tafamidis Era.
    Zaghlol R; Rater M; Schiffer W; Mitchell JD
    J Card Fail; 2022 Oct; 28(10):1519-1521. PubMed ID: 35988721
    [No Abstract]   [Full Text] [Related]  

  • 16. Response by Elliott et al to Letter Regarding Article, "Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy".
    Elliott P; Gundapaneni B; Sultan MB
    Circ Heart Fail; 2022 Jul; 15(7):e009637. PubMed ID: 35748240
    [No Abstract]   [Full Text] [Related]  

  • 17. Overview of Current and Emerging Therapies for Amyloid Transthyretin Cardiomyopathy.
    Maurer MS
    Am J Cardiol; 2022 Dec; 185 Suppl 1():S23-S34. PubMed ID: 36371281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimating the health benefits of timely diagnosis and treatment of transthyretin amyloid cardiomyopathy.
    Rozenbaum MH; Large S; Bhambri R; Stewart M; Young R; Doornewaard AV; Dasgupta N; Masri A; Nativi-Nicolau J
    J Comp Eff Res; 2021 Aug; 10(11):927-938. PubMed ID: 34142865
    [No Abstract]   [Full Text] [Related]  

  • 19. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
    Paton DM
    Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Developing Therapy for Transthyretin Amyloidosis.
    Campbell CM; Zhang K; Lenihan DJ; Witteles R
    Am J Med; 2022 Apr; 135 Suppl 1():S44-S48. PubMed ID: 35077703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.